编码登革热的mRNA-LNP疫苗优化prM/ENV蛋白质诱导没有ADE的保护性免疫力
Enzo LaMontia-Hankin1, Clayton J Wollner1, E Taylor Stone2
1Department of Microbiology and Immunology, University of Illinois College of Medicine, Chicago, Illinois, USA.
bioRxiv : the preprint server for biology
|December 3, 2025
概括
使用mRNA-LNP技术开发了一种新的四价值登革热病毒 (DENV) 疫苗. 这种疫苗可以保护所有四种DENV血型,并降低了抗体依赖增强 (ADE) 的风险.
科学领域:
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
- 疫苗开发 疫苗开发
背景情况:
- 登革热病毒 (DENV) 每年导致约4亿例感染,对于无知的个人没有批准的疫苗.
- 存在四种DENV血清型 (DENV1-4),由于潜在的抗体依赖增强 (ADE),使疫苗开发复杂化.
- 之前的研究表明,DENV-1 mRNA疫苗缺乏融合循环 (FL),可以保护DENV,避免ADE.
研究的目的:
- 开发和评估针对DENV血清型2,3,4的mRNA-LNP疫苗.
- 创建一个四价值疫苗,将单型DENV疫苗结合起来.
- 评估四价值疫苗的免疫性,保护性有效性和ADE潜力.
主要方法:
- 设计的mRNA-LNP疫苗为DENV 2,3和4编码prM-E蛋白质,包含ΔFL修饰和嵌合式E蛋白.
- 在小鼠中评估了疫苗免疫性和对致命同型DENV挑战的保护.
- 将单型疫苗配制成四价疫苗,并评估其在小鼠中的性能.
主要成果:
- 对DENV 2,3,4的单价mRNA-LNP疫苗引起了血清型特异性的中和抗体,并防止致命的同型挑战.
- 融合循环突变减少了接种疫苗的小鼠血清中的ADE.
- 四价疫苗诱导了对所有DENV血清型的中和反应,并提供了对致命挑战的保护.
结论:
- 单价DENV mRNA-LNP疫苗产生保护性免疫力并减轻ADE风险.
- 已经开发出第一代ADE改变的四价值DENV疫苗.
- 这种方法为安全有效的泛登革热疫苗提供了一个有希望的战略.
相关概念视频
02:28Leaky Scanning
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R stands for...
01:21Vaccines
Vaccines are among the most effective tools in preventive medicine, designed to prepare the immune system to recognize and combat infectious agents. By introducing antigens—substances that the immune system identifies as foreign—vaccines stimulate an adaptive immune response that leads to immunological memory. This immunological memory enables the body to mount a faster and more effective response upon future exposures to the actual pathogen.Vaccines can be categorized based on the type of...